TAR-200 Produces High CR Rates, Tolerability in BCG-unresponsive NMIBC

Treatment with TAR-200 produced complete responses and was well tolerated in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, according to preliminary data from the phase 2b SunRISe-1 trial.

Related Keywords

United States ,American ,Siamak Daneshmand ,American Urological Association Annual Meeting ,Clinical Research ,Bacillus Calmette Gu ,Urological Association Annual ,Keck Medicine ,Patients With Bacillus Calmette Guérin Unresponsive ,High Risk Non Muscle Invasive Bladder Cancer ,Tar 200 ,Phase 2b Sunrise 1 Trial ,Localized Gemcitabine ,Novel Intravesical Delivery System ,